Tomotherapy for prostate adenocarcinoma: A report on acute toxicity

Radiotherapy and Oncology

Volumn 84, Issue 2, 2007, Pages 171-176

  Keiler, Louis ^a   Dobbins, Donald ^a   Kulasekere, Ravi ^a   Einstein, Douglas ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

IGRT; IMRT; Prostate; Tomotherapy; Toxicity

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER TOMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION INJURY; UNIVARIATE ANALYSIS; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; URINARY BLADDER;

EID: 34548030221     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.07.012     Document Type: Article

References (39)

1. De Meerleer G., Vakaet L., Meersschout S., et al. Intensity modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60 (2004) 777-787
2. De Meerleer G., Vakaet L.A., De Gersem W.R., et al. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 47 (2000) 639-648
3. De Meerleer G., Villeirs G., Vakaet L., et al. The incidence of inclusion of the sigmoid colon and small bowel in the planning target volume in radiotherapy for prostate cancer. Strahlenther Onkol 180 (2004) 573-581
4. Dearnaley D.P., Khoo V.S., Norman A.R., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. Lancet 353 (1999) 267-272
5. Fiorino C., Reni M., Bolognesi A., et al. Intra- and inter-observer variability in contouring prostate and seminal vesicles: implications for conformal treatment planning. Radiother Oncol 47 (1998) 285-292
6. Hanks G.E., Hanlon A.L., Epstein B., and Horwitz E.M. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Biol Phys 54 (2002) 427-435
7. Hanks G.E., Schultheiss T.E., Hanlon A.L., et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Biol Phys 37 (1997) 543-550
8. Hanks G.E. Conformal radiation therapy for prostate cancer. Ann Med 32 (2000) 57-63
9. Hille A., Tows N., Schmidberger H., and Hess C.F. A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on the normal-tissue exposure. A potential for increasing the benefit/risk ratio. Strahlenther Onkol 181 (2005) 789-795
10. Hoffelt S.C., Marshall L.M., Garzotto M., Hung A., Holland J., and Beer T.M. A comparison of CT scan to transrectal ultrasound-measured prostate volume in untreated prostate cancer. Int J Radiat Oncol Biol Phys 57 (2003) 29-32
11. Jani A.B., Gratzle J., Muresan E., Ferrey K., and Martel M.K. Analysis of acute toxicity with use of transabdominal ultrasonography for prostate positioning during intensity-modulated radiotherapy. Urology 63 (2005) 504-508
12. Jani A.B., Su A., and Milano M.T. Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity. Urology 67 (2006) 147-151
13. Jennings B., and Muhlenkamp A. Systematic misperception (oncology patients' self-reported affective states and their caregivers' perceptions). Cancer Nurs 4 (1981) 485-489
14. Karlsdottir A., Johannessen D.C., Muren L.P., Wentzel-Larson T., and Dahl O. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 71 (2004) 43-53
15. Koper P.C., Stroom J.C., van Putten W.L., et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 43 (1999) 727-734
16. Lee Y.K., Bollet M., Charles-Edwards G., et al. Radiotherapy treatment planning of prostate cancer using magnetic resonance imaging alone. Radiother Oncol 66 (2003) 203-216
17. Leibovich B.C., Blute M.L., Bostwick D.G., et al. Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology 56 (2000) 726-729
18. Livsey J.E., Wylie J.P., Swindell R., Khoo V.S., Cowan R.A., and Longue J.P. Do differences in target volume definition in prostate cancer lead to clinically relevant differences in normal tissue toxicity?. Int J Radiat Oncol Biol Phys 60 (2004) 1076-1081
19. McLaughlin P.W., Troyer S., Berri S., et al. Functional anatomy of the prostate: implications for treatment planning. Int J Radiat Oncol Biol Phys 63 (2005) 479-491
20. Monti C.R., Nakamura R.A., Ferrigno R., Rossi Jr. A., Kawakami N.S., and Trevisan F.A. Salvage conformal radiotherapy for biochemical recurrent prostate cancer after radical prostatectomy. Int Braz J Urol 32 (2001) 416-426
21. Muanza T.M., Albert P.S., Smith S., et al. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 1316-1321
22. Payne G.S., and Leach M.O. Applications of Magnetic Resonance Spectroscopy in radiotherapy treatment planning. Br J Radiol 79 (2006) S16-S26
23. Parker C.C., Damyanovich A., Haycocks T., et al. Magnetic resonance imaging in the radiation treatment planning of localized prostate cancer using intra-prostatic fiducial markers for computed tomography co-registration. Radiother Oncol 66 (2003) 217-224
24. Peeters S.T., Heemsbergen W.D., van Putten W.L., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
25. Pollack A., Zagars G.K., Starkschall G., et al. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 34 (1996) 555-564
26. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Biol Phys 53 (2002) 1097-1105
27. Soete G., Verellen D., Michielsen D., Rappe B., Keuppen F., and Storme G. Image-guided conformation arc therapy for prostate cancer: early side effects. Int J Radiat Oncol Biol Phys 66 (2006) S141-S144
28. Storey M.R., Pollack A., Zagars G., Smith L., Antolak J., and Rosen I. Complications from dose escalation in prostate cancer (preliminary results of a randomized trial). Int J Radiat Oncol Biol Phys 48 (2000) 635-642
29. Taussky D., Schneider U., Rousson V., and Pescia R. Patient-reported toxicity correlated to dose-volume histograms of the rectum in radiotherapy of the prostate. Am J Clin Oncol 26 (2003) e144-e149
30. Teh B.S., Mai W.Y., Uhl B.M., et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys 49 (2001) 705-712
31. Teh B.S., Mai W.Y., Augspurger M.E., et al. Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer. Int J Radiat Oncol Biol Phys 49 (2001) 465-472
32. Wei J.T., Dunn R.L., Litwin M.S., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000) 899-905
33. Welsh J.S., Patel R.R., Ritter M.A., Harari P.M., Mackie T.R., and Mehta M.P. Helical tomotherapy: an innovative technology and approach to radiation therapy. Technol Cancer Res Treat 1 (2002) 311-316
34. Woel R., Beard C., Chen M.H., et al. Acute gastrointestinal, genitourinary and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization. Int J Radiat Oncol Biol Phys 62 (2005) 392-396
35. Youngblood M., Williams P., Eyles H., et al. A comparison of two methods of assessing cancer therapy-related symptoms. Cancer Nurs 17 (1994) 37-44
36. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated radiation therapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
37. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
38. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55 (2000) 241-249
39. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116